Clinical trial NCT04672421: The Efficacy and Safety of Medicurtain® in Patients With Total Laparoscopic Hysterectomy (Pivotal Study)
Official title: A Comparative, Evaluator Blinded, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of Medicurtain® in Patients With Total Laparoscopic Hysterectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Laparoscopy
Tissue Adhesion, Surgery-Induced
Leiomyoma of the Uterine Body
Keywords: Medicurtain®
Sodium hyaluronate
Hydroxyethylstarch
Anti-adhesion barrier
Lead sponsor: Shin Poong Pharmaceutical Co. Ltd.
Sponsor class: INDUSTRY
First posted: 2020-12-17
Enrollment: 107
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study was designed to assess the safety and efficacy of MEDICURTAIN. Patients who underwent total laparoscopic hysterectomy were randomly assigned either into Medicurtain® treatment group or non-treatment control group. Adhesion formations at 8 weeks after the index surgery were compared between the two groups by using the well-defined grade scale and image recording.

Detailed description: This study was designed as multi-center, randomized, evaluator-blinded, comparative study. Subjects were woman between 20\~80 years of age reserved with total laparoscopic hysterectomy. Subject screening was conducted for the subject who signed an informed consent form. Subjects who met the inclusion criteria were randomly assigned into either treatment (Medicurtain®) or control group.

Each subject visit clinic for follow-up examination 1week (Visit 2) and 8 weeks (Visit 3) after the index surgery and before the visit subjects were received phone calls. Since the target population was the patient who scheduled elective total laparoscopic hysterectomy, subjects who met the inclusion/exclusion criteria after the examination for the surgery signed on the informed consent at Visit 1 (Baseline: 0 day) and randomly assigned either into the treatment and control group.

At visit 2 (1week±2days), 1week after the index surgery adverse events and general health were examined. At visit 3 (8week±5days), 8 weeks after the index surgery, the investigator inserted endoscope into abdominal cavity and took video clip and still images. If it was necessary, adhesion was removed surgically. An independent evaluator evaluated the records and graded the adhesion rate and its severity according to the grading system. If it was difficult to collect images with endoscope, the investigators recorded his observation for statistical analysis.

The investigator inserted endoscope into abdominal cavity and took video clip and still images at 8weeks after total laparoscopic hysterectomy to evaluate the adhesion formation and its grade. An independent evaluator evaluated the records and graded the adhesion rate and its severity according to the grading system. If it was difficult to collect images with endoscope, the investigators recorded his observation for statistical analysis. The adhesion grading system was proposed by American Fertility Society (AFS) in 1988, grades adhesion with Grade 0, Grade 1, Grade2 and Grade 3. Grade 0 means there is no adhesion formation, Grade 1\~Grade 3 means there is adhesion formed, severity increases with the grade. Adhesion rate and grade were evaluated between the treatment and control groups suing Grade 0\~3 scales.

General safety of the study device was evaluated based on the adverse event rate, laboratory tests, ECG test. The laboratory tests were conducted before and after the index surgery to evaluate whether the device cause toxicity such as hepatic and renal toxicity for safety evaluation.

Eligibility criteria: Inclusion Criteria:

* Woman who is between 20\~80 years of age.
* Woman who is reserved with total laparoscopic hysterectomy like:

  * Malignant neoplasm of cervix
  * Malignant neoplasm of uterine body
  * Unspecified malignant neoplasm of cervical region
  * Other and unspecified malignant neoplasm of the female reproductive system
  * Carcinoma in situ of the cervix
  * Other and unspecified carcinoma in situ of the reproductive system Leiomyoma of the uterus
  * Other benign neoplasms of uterus
  * Neoplasm of uncertain behavior of uterus
  * Endometriosis
  * Polyp of corpus uteri
  * Other noninflammatory disorders of uterus, except cervix
  * Cervical dysplasia
  * Congenital malformations of uterus and cervix
  * Injury of uterus
* Woman who signed and informed consent.

Exclusion Criteria:

* Presence of tumor or inflammatory disease in other organs after the laparoscopy or laparoscopic surgery
* Subjects with a history of open surgery or laparoscopic surgery
* Subject who is not eligible for anesthesia or re-operation due to other disease confirmed by investigator
* Subject who is not eligible for re-operation or laparoscopy after laparoscopic surgery
* Subjects using coagulant and subjects with lymphoid disease
* Diabetic subjects administrating oral or parenteral glucose-lowering drugs
* Patients with autoimmune diseases or immune disorders
* Liver disease or kidney disease, surgical subjects including open surgery of gastrointestinal or urinary system
* Subjects judged as inadequate by investigator

Primary outcomes:
measure: Comparison of the adhesion rate between the groups
timeFrame: 8 weeks after surgery
Secondary outcomes:
measure: Comparison of adhesion grade based on the severity between the groups
timeFrame: 8 weeks after surgery
Other outcomes:
measure: The incidence rate of adverse events
timeFrame: follow up to 8 weeks
measure: The incidence rate of adverse device event
timeFrame: follow up to 8 weeks
measure: The incidence rate of serious adverse events
timeFrame: follow up to 8 weeks
measure: QT interval on a 12-lead electrocardiogram (ECG) tracing
timeFrame: follow up to 8 weeks
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
state: Seoul Asan Medical Center Gil, Songpa-gu
Study officials:
affiliation: Asan Medical Center, Seoul Asan Medical Center Gil, Songpa-gu, Seoul, Korea
name: Young-Tak Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cheil General Hospital & Women's Healthcare Center, 1-19 Mukjeong-dong, Jung-gu, Seoul, Korea
name: Tae Jin Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Kangdong Sacred Heart Hospital, (Gil 1dong445) 150, Seongnae-gil, Gwangsan-gu, Gwangju, Korea
name: Yong-Il Kwon, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: